Transcatheter Treatment of Tricuspid Valve Regurgitation With the TriFlo Tricuspid Flow Optimizer (TFO) System
Tricuspid Regurgitation induces an asymmetric enlargement of the tricuspid valve (TV) annulus causing a reduction of leaflets coaptation. Annular dilation continues even after surgical treatment. The progressive nature of TR, inadequate surgical treatment, and high-risk patient population make TR an ideal target for transcatheter therapy. The TriFlo TFO System introduces a new concept for the treatment of tricuspid regurgitation. Its commissural anchoring is designed to respect TV leaflet integrity, mobility, and maintain RV contractility.
100 Clinical Results associated with TriFlo Cardiovascular, Inc.
0 Patents (Medical) associated with TriFlo Cardiovascular, Inc.
100 Deals associated with TriFlo Cardiovascular, Inc.
100 Translational Medicine associated with TriFlo Cardiovascular, Inc.